Angiogenesis, the formation of new blood vessels, is a complex and dynamic process
regulated by various pro-and anti-angiogenic molecules, which plays a crucial role in tumor …

Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Abstract Background KRAS G12C is a mutation that occurs in approximately 3 to 4% of
patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has …

Background In a previous phase 3 trial, treatment with trifluridine–tipiracil (FTD–TPI)
prolonged overall survival among patients with metastatic colorectal cancer. Preliminary …

Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …

Background Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has
shown clinical activity in pretreated patients with several tumor types, including colorectal …

Background Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS
activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions …

Angiogenesis is an essential process in normal development and in adult physiology, but
can be disrupted in numerous diseases. The concept of targeting angiogenesis for treating …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …